WO2003099226A2 - Antibody peg positional isomers, compositions comprising same, and use thereof - Google Patents
Antibody peg positional isomers, compositions comprising same, and use thereof Download PDFInfo
- Publication number
- WO2003099226A2 WO2003099226A2 PCT/US2003/016619 US0316619W WO03099226A2 WO 2003099226 A2 WO2003099226 A2 WO 2003099226A2 US 0316619 W US0316619 W US 0316619W WO 03099226 A2 WO03099226 A2 WO 03099226A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- peg
- composition
- cdp870
- positional isomer
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 43
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract description 43
- 229960003115 certolizumab pegol Drugs 0.000 claims abstract description 28
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 11
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 9
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 70
- 229920000642 polymer Polymers 0.000 claims description 22
- 239000012636 effector Substances 0.000 claims description 15
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 10
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 9
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 9
- 235000001014 amino acid Nutrition 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical group OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 6
- 150000002019 disulfides Chemical class 0.000 claims description 5
- 235000018102 proteins Nutrition 0.000 claims description 5
- 108010024636 Glutathione Proteins 0.000 claims description 3
- 229960003180 glutathione Drugs 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 14
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 10
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 abstract description 7
- 102000057041 human TNF Human genes 0.000 abstract description 5
- 230000000890 antigenic effect Effects 0.000 abstract description 4
- 208000035475 disorder Diseases 0.000 abstract description 4
- 201000008482 osteoarthritis Diseases 0.000 abstract description 3
- 230000001154 acute effect Effects 0.000 abstract description 2
- 230000001684 chronic effect Effects 0.000 abstract description 2
- 230000004957 immunoregulator effect Effects 0.000 abstract description 2
- 241000282414 Homo sapiens Species 0.000 description 27
- -1 hydroxy, methyl Chemical group 0.000 description 20
- 238000000034 method Methods 0.000 description 15
- 238000011282 treatment Methods 0.000 description 13
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 241001529936 Murinae Species 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 206010040070 Septic Shock Diseases 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 6
- 239000012634 fragment Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 206010014824 Endotoxic shock Diseases 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 208000011231 Crohn disease Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940124446 critical care medicine Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 229920001427 mPEG Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000009824 affinity maturation Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
- 210000001322 periplasm Anatomy 0.000 description 2
- 229920001281 polyalkylene Polymers 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 150000003923 2,5-pyrrolediones Chemical group 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 101710099705 Anti-lipopolysaccharide factor Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 241001415846 Procellariidae Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102000009270 Tumour necrosis factor alpha Human genes 0.000 description 1
- 108050000101 Tumour necrosis factor alpha Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000003978 alpha-halocarboxylic acids Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000781 anti-lymphocytic effect Effects 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 201000005008 bacterial sepsis Diseases 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 231100000284 endotoxic Toxicity 0.000 description 1
- 230000002346 endotoxic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 150000002678 macrocyclic compounds Chemical class 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002859 polyalkenylene Polymers 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Definitions
- the present invention relates to recombinant protein PEG positional isomers. More specifically, it relates to PEG positional isomers of an antibody having specificity for antigenic determinants of human tumor necrosis factor alpha (TNF ⁇ ). More specifically, it relates to PEG positional isomers of CDP870. The present invention also relates to compositions comprising the PEG positional isomers and therapeutic uses of the antibody.
- variable domains In an antibody molecule, there are two heavy chains and two light chains. Each heavy chain and each light chain has at its N-terminal end a variable domain. Each variable domain is composed of four framework regions (FRs) alternating with three complementarily determining regions (CDRs). The residues in the variable domains are conventionally numbered according to a system devised by Kabat et al. This system is set forth in Kabat et al, 1987, in Sequences of
- Kabat residue designations do not always correspond directly with the linear numbering of the amino acid residues.
- the actual linear amino acid sequence may contain fewer or additional amino acids than in the strict Kabat numbering corresponding to a shortening of, or insertion into, a structural component, whether framework or CDR, of the basic variable domain structure.
- the correct Kabat numbering of residues may be determined for a given antibody by alignment of residues of homology in the sequence of the antibody with a "standard" Kabat numbered sequence.
- the CDRs of the heavy chain variable domain are located at residues 31- 335 (CDRHI), residues 50-65 (CDRH2) and residues 95-102 (CDRH3) according to the Kabat numbering.
- Application EP-A-0239400 which discloses a process in which the CDRs of a mouse monoclonal antibody are grafted onto the framework regions of the variable domains of a. human immunoglobulin by site directed mutagenesis using long oligonucleotides.
- the CDRs determine the antigen binding specificity of antibodies and are relatively short peptide sequences carried on the framework regions of the variable domains.
- TNF ⁇ is a pro-inflammatory cytokine that is released by and interacts with cells of the immune system.
- TNF ⁇ is released by macrophages that have been activated by lipopolysaccharides (LPS) of gram negative bacteria.
- LPS lipopolysaccharides
- TNF ⁇ has also been shown to be up-regulated in a number of human diseases, including chronic diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, and multiple sclerosis.
- Mice transgenic for human TNF ⁇ produce high levels of TNF ⁇ constitutively and develop a spontaneous, destructive polyarthritis resembling rheumatoid arthritis (Kaffer et al. , EMBO J. , Jj), 4025 4031 , 1991 ).
- TNF ⁇ is therefore referred to as a pro-inflammatory cytokine.
- Monoclonal antibodies against TNF ⁇ have been described in the prior art.
- Bodmer et al (Critical Care Medicine, 2 ⁇ , S441-S446, 1993) and Wherry et al, (Critical Care Medicine, 21, S436S440, 1993) discuss the therapeutic potential of anti- TNF ⁇ antibodies in the treatment of septic shock.
- the use of anti-TNF ⁇ antibodies in the treatment of septic shock is also discussed by Kirschenbaum et al. , (Critical Care Medicine, 26, 1625-1626, 1998). Collagen-induced arthritis can be treated effectively using an anti-TNF ⁇ monoclonal antibody (Williams et al. (PNAS-USA, 89, 9784-9788, 1992)).
- TNF ⁇ blocking agents are administered to patients suffering from rheumatoid arthritis, they reduce inflammation, improve symptoms, and retard joint damage (McKown et al. (Arthritis Rheum., 42, 12041208, 1999).
- anti-TNF ⁇ antibodies used in the treatment of rheumatoid arthritis and 20 Crohn's disease is discussed in Feldman et al, (Transplantation Proceedings, 30, 41264127, 1998), Adorini et al, (Trends in Immunology Today, 18, 209-211, 1997) and in Feldman et al, (Advances in Immunology, 64, 283-350, 1997).
- the antibodies to TNF ⁇ used in such treatments are generally chimeric antibodies, such as those described in US-A5919452.
- TNF ⁇ blocking products are currently licensed for the treatment of rheumatoid arthritis.
- the first called etanercept, is marketed by Immunex Corporation as Enbrel M . It is a recombinant fusion protein comprising two p75 soluble TNF-receptor domains linked to the Fc portion of a human immunoglobulin.
- the second called infliximab, is marketed by Centocor Corporation as RemicadeTM. It is a chimeric antibody having murine anti-TNF ⁇ variable domains and human IgG I constant domains.
- the prior art recombinant anti-TNF ⁇ antibody molecules generally have a reduced affinity for TNF ⁇ compared to the antibodies from which the variable regions or CDRs are derived, generally have to be produced in mammalian cells and are expensive to manufacture.
- Prior art anti-TNF ⁇ , antibodies are described in Stephens etal, (Immunology, 85, 668-674, 1995), GB-A-2 246 570 and GB- A-2 297 145.
- WO 01/94585 describes antibody molecules having high affinity for TNF ⁇ and low immunogenicity in humans, which can be used repeatedly and produced easily and efficiently, to treat chronic inflammatory diseases.
- This invention comprises recombinant protein PEG positional isomers, preferably, PEG positional isomers of an antibody having specificity for antigenic determinants of human tumour necrosis factor alpha (TNF ⁇ ).
- the present invention also relates to compositions comprising the isomers and therapeutic uses of the antibody.
- Figure 1 shows the amino acid sequence of the light and heavy chains of CDP870, the intramolecular disulfide pairing, the predominant intermolecular disulfide pairing between the light and heavy chains and the cysteine for PEG conjugation.
- Figure 2 shows the amino acid sequence of the light and heavy chains of the CDP870 PEG positional isomer where the PEG is attached at Cys 214 of the light chain (CDP870-PEG-1214).
- the residues of interest (light chain cys-214, heavy chain cys-221 and heavy chain cys-227 are highlighted.
- the present invention provides recombinant protein PEG positional isomers, having an alternate PEG attachment site.
- An "antibody PEG positional isomer” is defined as an antibody having a PEG attachment site other than the predominant PEG attachment site.
- the PEG positional isomer is of an antibody having specificity for antigenic determinants of human tumor necrosis factor alpha (TNF ⁇ ).
- TNF ⁇ antibody is a TNF ⁇ antibody disclosed in WO 01/04585.
- the antibody is CDP870.
- WO 01/04585 provides an antibody molecule having specificity for TNF ⁇
- TNF ⁇ comprising a heavy chain wherein the variable domain comprises a CDR (as defined by Kabat et al, (supra)) having the sequence given as HI in Figure 3 of WO 01/04585 (SEQ ID NO: 1 of WO 01/04585) for CDRH1, as H2' in Figure 3 of WO 01/04585 (SEQ ID NO: 2 of WO 01/04585) or as H2 in Figure 3 of WO 01/04585 (SEQ ID NO: 7 of WO 01/04585) for CDRH2 or as H3 in Figure 3 of WO 01/04585 (SEQ ID NO: 3 of WO 01/04585) for CDRH3.
- CDR as defined by Kabat et al, (supra)
- the antibody molecule of WO 01/04585 comprises at least one CDR selected from H 1, H2' or H2 and H3 (SEQ ID NO: 1; SEQ ID NO: 2 or SEQ ID NO: 7 and SEQ ID NO: 3 of WO 01/04585) for the heavy chain variable domain.
- the antibody molecule comprises at least two and more preferably all three CDRs in the heavy chain variable domain.
- an antibody molecule having specificity for human TNF ⁇ comprising a light chain wherein the variable domain comprises a CDR (as defined by Kabat et al, (supra)) having the sequence given as LI in Figure 3 of WO 01/04585 (SEQ ID NO: 4 of WO 01/04585) for CDRL1, L2 in Figure 3 of WO 01/04585 (SEQ ID NO: 5 of WO 01/04585) for CDRL2 or L3 in Figure 3 of WO 01/04585 (SEQ ID NO: 6 of WO 01/04585) for CDRL3.
- CDR as defined by Kabat et al, (supra)
- the antibody molecule of WO 01 /04585 comprises at least one CDR selected from LI, L2, and L3 (SEQ ID NO: 4 to SEQ ID NO: 6 of WO 01/04585) for the light chain variable domain.
- the antibody molecule comprises at least two and more preferably all three CDRs in the light chain variable domain.
- the antibody molecules of WO 01 /04585 preferably have a complementary light chain or a complementary heavy chain, respectively.
- the antibody molecule of WO 01/04585 comprises a heavy chain wherein the variable domain comprises a CDR (as defined by Kabat et al, (supra)) having the sequence given as HI in Figure 3 of WO 01/04585 (SEQ ID NO: 1 of WO 01/04585) for CDRH1, as H2' or H2 in Figure 3 of WO 01/04585 (SEQ ID NO: 2 or SEQ ID NO: 7 of WO 01/04585) for CDRH2 or as H3 in Figure 3 of WO 01/04585 (SEQ ID NO: 3 of WO 01/04585) for CDRH3 and a light chain wherein the variable domain comprises a CDR (as defined by Kabat et al, (supra)) having the sequence given as LI in Figure 3 of WO 01/04585 (SEQ ID NO:4 of WO 01/04585) for CDRL1, as L2 in Figure 3 of WO 01/04585 (SEQ ID NO:5 of WO 01
- the CDRs given in SEQ IDS NOS: 1 and 3 to 7 of WO 01/04585 and in Figure 3 of WO 01/04585 are derived from a mouse monoclonal antibody hTNF40.
- SEQ ID NO: 2 of WO 01/04585 consists of a hybrid CDR.
- the hybrid CDR comprises part of heavy chain CDR2 from mouse monoclonal antibody hTNF40 (SEQ ID NO: 7 of WO 01/04585) and part of heavy chain CDR2 from a human group 3 germline V region sequence.
- WO 01/04585 light chain
- Figure 7 of WO 01/04585 dashed chain
- This mouse antibody is referred to below as "the donor antibody”.
- a first alternatively embodiment of WO 01/04585 is the mouse monoclonal antibody hTNF40 having the light and heavy chain variable domain sequences shown in Figure 6 of WO 01/04585 (SEQ ID NO: 99 of WO 01/04585) and Figure 7 of WO 01/04585 (SEQ ID NO: 100 of WO 01/04585), respectively.
- the light chain constant region of hTNF40 is kappa and the heavy chain constant region is IgG2a.
- the antibody according to either of the first and second aspects of WO 01/04585 is a chimeric mouse/human antibody molecule, referred to herein as the chimeric hTNF40 antibody molecule.
- the chimeric antibody molecule comprises the variable domains of the mouse monoclonal antibody hTNF40 (SEQ ID NOS : 99 and 100 of WO 01/04585) and human constant domains.
- the chimeric hTNF40 antibody molecule comprises the human C kappa domain (Hieter et al, Cell, 22, 197-207, 1980; Genebank accession number J00241) in the light chain and the human gamma 4 domains (Flanagan et al, Nature, 300, 709-713, 1982) in the heavy chain.
- the antibody is a CDR-grafted antibody molecule.
- a CDR-grafted antibody molecule refers to an antibody molecule wherein the heavy and/or light chain contains one or more CDRs (including, if desired, a hybrid CDR) from the donor antibody (e.g. a murine monoclonal antibody) grafted into a heavy and/or light chain variable region framework of an acceptor antibody (e.g. a human antibody).
- a CDR-grafted antibody has a variable domain comprising human acceptor framework regions as well as one or more of the donor CDRs referred to above.
- any appropriate acceptor variable region framework sequence may be used having regard to the class/type of the donor antibody from which the CDRs are derived, including mouse, primate and human framework regions.
- human frameworks of WO 01/04585 are KOL, NEWM, REI, EU, TUR, TEI, LAY, and POM (Kabat et al. (supra)).
- KOL and NEWM can be used for the heavy chain
- REI can be used for the light chain and EU
- LAY and POM can be used for both the heavy chain and the light chain.
- the preferred framework regions for the light chain are the human group 1 framework regions shown in Figure 1 (SEQ ID NOS: 83, 85, 87 and 89 of WO 01/04585).
- the preferred framework regions for the heavy chain are the human group 1 and group 3 framework regions shown in Figure 2 (SEQ ID NOS: 91, 93, 95 and 97 and SEQ ID NOS: 106, 107, 108 and 109 of WO 01/04585), respectively.
- SEQ ID NOS: 91, 93, 95 and 97 and SEQ ID NOS: 106, 107, 108 and 109 of WO 01/04585) respectively.
- it is preferred to use as the acceptor antibody one having chains which are homologous to the chains of the donor antibody.
- acceptor heavy and light chains do not necessarily need to be derived from the same antibody and may, if desired, comprise composite chains having framework regions derived from different chains.
- the framework regions need not have exactly the same sequence as those of the acceptor antibody. For instance, unusual residues may be changed to more frequently occurring residues for that acceptor chain class or type. Alternatively, selected residues in the acceptor framework regions may be changed so that they correspond to the residue found, at the same position in the donor antibody. Such changes should be kept to the minimum necessary to recover the affinity of the donor antibody.
- a protocol for selecting residues in the acceptor framework regions which may need to be changed is set forth in WO 91/09967.
- the acceptor heavy chain has human group 1 framework regions (shown in Figure 2 of WO 01/04585) (SEQ ID NOS: 91, 93, 95 and 97 of WO 01/04585), then the acceptor framework regions of the heavy chain comprise, in addition to one or more donor CDRs, donor residues at positions 28, 69 and 71 (according to Kabat et al. (supra)).
- the acceptor heavy chain has group 1 framework regions
- the acceptor framework regions of the heavy chain comprise, in addition to one or more donor CDRs, donor residues at positions 28, 38, 46, 67, 69, and 71 (according to Kabat et al. (supra).
- the acceptor heavy chain has human group 3 framework regions (shown in Figure 2 of WO 01/04585) (SEQ ID NOS: 106, 107, 108 and 109 of WO 01/04585), then the acceptor framework regions of the heavy chain comprise, in addition to one or more donor CDRs, donor residues at positions 27, 28, 30, 48, 49, 69, 71, 73, 76 and 78 (according to Kabat et al. (supra)).
- the acceptor light chain has human group I framework regions (shown in Figure 1 of WO 01/04585) (SEQ ID NOS: 83, 85, 87 and 89 of WO 01/04585) then the acceptor framework regions of the light chain comprise donor residues at positions 46 and 60 (according to Kabat et al. (supra)).
- Donor residues are residues from the donor antibody, i.e. the antibody from which the CDRs were originally derived.
- the antibody molecule of WO 01/04585 may comprise: a complete antibody molecule, having full length heavy and light chains; a fragment thereof, such as a Fab, modified Fab, Fab', F(ab') 2 or Fv fragment; a light chain or heavy chain monomer or dimer; a single chain antibody, e.g. a single chain Fv in which the heavy and light chain variable domains are joined by a peptide linker. Similarly, the heavy and light chain variable regions may be combined with other antibody domains as appropriate.
- the antibody molecule of WO 01/04585 is a Fab fragment.
- the Fab fragment has a heavy chain having the sequence given as SEQ ID NO: 111 of WO 01/04585 and a light chain having the sequence given as SEQ ID NO: 113 of WO 01/04585.
- the amino acid sequences given in SEQ ID NO: 111 and SEQ ID NO: 113 of WO 01/04585 are preferably encoded by the nucleotide sequences given in SEQ ID NO: 110 and SEQ ID NO: 112 of WO 01/04585, respectively.
- the antibody molecule of WO 01/04585 is a modified Fab fragment wherein the modification is the addition to the C- terminal end of its heavy chain one or more amino acids to allow the attachment of an effector or reporter molecule.
- the additional amino acids form a modified hinge region containing one or two cysteine residue to which the effector or reporter molecule may be attached.
- Such a modified Fab fragment preferably has a heavy chain having the sequence given as SEQ ID NO: 115 of WO 01/04585 and the light chain having the sequence given as SEQ ID NO: 113 of WO 01/04585.
- a preferred effector group of WO 01/04585 is a polymer molecule, which may be attached to the modified Fab fragment to increase its half-life in vivo.
- the polymer molecule may, in general, be a synthetic or a naturally occurring polymer, for example an optionally substituted straight or branched chain polyalkylene, polyalkenylene or polyoxyalkylene polymer or a branched or unbranched polysaccharide, e.g. a homo- or hetero- polysaccharide.
- Particular optional substituents which may be present on the above- mentioned synthetic polymers, include one or more hydroxy, methyl or methoxy groups.
- Particular examples of synthetic polymers include optionally substituted straight or branched chain poly(ethyleneglycol), poly(propylene glycol) poly(vinylalcohol) or derivatives thereof, especially optionally substituted poly(ethyleneglycol) such as methoxypoly(ethyleneglycol) or derivatives thereof.
- Particular naturally occurring polymers include lactose, amylose, ⁇ dextran, glycogen or derivatives thereof. "Derivatives" as used herein is intended to include reactive derivatives, for example thiol-selective reactive groups such as maleimides and the like.
- the reactive group may be linked directly or through a linker segment to the polymer. It will be appreciated that the residue of such a group will in some instances form part of the product as the linking group between the antibody fragment and the polymer.
- the size of the polymer may be varied as desired, but will generally be in an average molecular weight range from 500Da to 50000Da, preferably from 5000 to 40000Da and more preferably from 25000 to 40000Da.
- the polymer size may in particular be selected on the basis of the intended use of the product.
- Particularly preferred polymers include a polyalkylene polymer, such as a poly(ethyleneglycol) or, especially, a methoxypoly(ethyleneglycol) or a derivative thereof, and especially with a molecular weight in the range from about 25000Da to about 40000Da.
- Each polymer molecule attached to the modified antibody fragment may be covalently linked to the sulphur atom of a cysteine residue located in the fragment.
- the covalent linkage will generally be a disulphide bond or, in particular, a sulphur-carbon bond.
- the antibody fragment may have one or more effector or reporter molecules attached to it.
- the effector or reporter molecules may be attached to the antibody fragment through any available amino acid side-chain or terminal amino acid functional group located in the fragment, for example any free amino, imino, hydroxyl or 5 carboxyl group.
- An activated polymer may be used as the starting material in the preparation of polymer-modified antibody fragments as described above.
- the activated polymer may be any polymer containing a thiol reactive group such as an ⁇ -halocarboxylic acid or ester, e.g. iodoacetamide, an imide, e.g. maleimide, a vinyl sulphone, or a disulphide.
- a thiol reactive group such as an ⁇ -halocarboxylic acid or ester, e.g. iodoacetamide, an imide, e.g. maleimide, a vinyl sulphone, or a disulphide.
- Such starting materials may be obtained commercially (for example from Shearwater Polymers Inc., Huntsville, AL, USA) or may be prepared from commercially available starting materials using conventional chemical procedures.
- an antibody fragment linked to an effector or reporter molecule this may be prepared by standard chemical or recombinant DNA procedures in which the antibody fragment is linked either directly or via a coupling agent to the effector or reporter molecule either before or after reaction with the activated polymer as appropriate.
- Particular chemical procedures include, for example, those described in WO 93/62331, WO 92/22583, WO 90/00195 and WO 89/01476.
- the effector or reporter molecule is a protein or polypeptide the linkage may be achieved using recombinant DNA procedures, for example as described in WO 86/01533 and EP-A 392 745.
- the modified Fab fragment of WO 01/04585 is PEGylated (i.e. has PEG (poly(ethyleneglycol)) covalently attached thereto) according to the method disclosed in EP-A 948 544.
- the antibody molecule of WO 01/04585 is a PEGylated modified Fab fragment as shown in Figure 13 of WO ' 01/04585.
- the modified Fab fragment has a maleimide group covalently linked to a single thiol group in a modified hinge region. A lysine residue is covalently linked to the maleimide group.
- lysine linked PEGs are referred to as "branched PEG” or "U-PEG” as disclosed in US 6,113,906; US 5,919,455; US 5,643,575; and US 5,932,462.
- the heavy chain of the antibody part has the sequence given as SEQ ID NO: 115 of WO 01/04585 and the light chain has the sequence given in SEQ ID NO: 113 of WO 01/04585.
- This compound is referred to in WO 01/04585 as CDP870.
- the constant region domains of the antibody molecule of WO 01/04585, if present, may be selected having regard to the proposed function of the antibody molecule, and in particular the effector functions which may be required.
- the constant region domains may be human IgA, IgD, IgE, IgG or IgM domains.
- human IgG constant region domains may be used, especially of the IgGl and IgG3 isotypes when the antibody molecule is intended for therapeutic uses and antibody effector functions are required.
- IgG2 and IgG4 isotypes may be used when the antibody molecule is intended for therapeutic purposes and antibody effector functions are not required, e.g. for simply blocking TNF ⁇ activity.
- the antibody molecule of WO 01/04585 may have an effector or a reporter molecule attached to it.
- it may have a macrocycle, for chelating a heavy metal atom, or a toxin, such as ricin, attached to it by a covalent bridging structure.
- procedures of recombinant DNA technology may be used to produce an antibody molecule in which the Fc fragment (CH2, CH3 and hinge domains), the CH2 and CH3 domains or the CH3 domain of a complete immunoglobulin molecule has (have) been replaced by, or has attached thereto by peptide linkage, a functional non- immunoglobulin protein, such as an enzyme or toxin molecule.
- the antibody molecule of WO 01/04585 preferably has a binding affinity of at least 0.85xl0 "10 M, more preferably at least 0.75xl0 "10 M and most preferably at least 0.5x10 "10 M. (It is worth noting that the preferred humanised antibody molecule of WO 01/04585, as described below, has an affinity of about 0.5xl0 "10 M, which is better than the affinity of the murine monoclonal antibody from which it is derived. The murine antibody has an affinity of about 0.85x 10 "10 M.
- the antibody molecule of WO 01/04585 comprises the light chain variable domain hTNF40-gLl (SEQ ID NO: 8 of WO 01/04585) and the heavy chain variable domain gh3hTNF40.4 (SEQ ID NO: 11 of WO 01/04585).
- the sequences of the variable domains of these light and heavy chains are shown in Figures 8 and 11 of WO 01/04585, respectively.
- WO 01/04585 also relates to variants of the antibody molecule, which have an improved affinity for TNF ⁇ . Such variants can be obtained by a number of affinity maturation protocols including mutating the CDRs (Yang et al, J. Mol.
- WO 01/04585 also provides a DNA sequence encoding the heavy and/or light chain(s) of the antibody molecule.
- WO 01/04585 also relates to a cloning or expression vector comprising one or more DNA sequences.
- the cloning or expression vector comprises two DNA sequences, encoding the light chain and the heavy chain of the antibody molecule.
- WO 01/04585 also relates to host cell/vector systems used for expression of the DNA sequences encoding the antibody molecule. Bacterial, for example E.
- coli and other microbial systems may be used, in part, for expression of antibody fragments such as Fab and F(ab') 2 fragments, and especially Fv fragments and single chain antibody fragments, for example, single chain Fvs.
- Eukaryotic, e.g. mammalian, host cell expression systems may be used for production of larger antibody molecules, including complete antibody molecules. Suitable mammalian host cells include CHO, myeloma or hybridoma cells.
- WO 01/04585 also provides a process for the production of an antibody molecule comprising culturing a host cell comprising a vector under conditions suitable for leading to expression of protein from DNA encoding the antibody molecule, and isolating the antibody molecule.
- the process for the production of the antibody molecule of WO 01/04585 comprises culturing E. coli comprising an E. coli expression vector comprising the DNA sequence under conditions suitable for leading to expression of protein from the DNA sequence and isolating the antibody molecule.
- the antibody molecule may be secreted from the cell or targeted to the periplasm by suitable signal sequences. Alternatively, the antibody molecules may accumulate within the cell's cytoplasm. Preferably the antibody molecule is targeted to the periplasm.
- the antibody molecule may comprise only a heavy or light chain polypeptide, in which case only a heavy chain or light chain polypeptide coding sequence needs to be used to transfect the host cells.
- the cell line may be transfected with two vectors, a first vector encoding a light chain polypeptide and a second vector encoding a heavy chain polypeptide.
- a single vector may be used, the vector including sequences encoding light chain and heavy chain polypeptides.
- -An embodiment of the present invention is a CP870 isomer having a PEG on Cys 214 of the light chain (CDP870-PEG-1214).
- the predominant CDP870 antibody form has a disulfide linkage between Cys 214 of the light chain and Cys 221 of the heavy chain and PEG attachment at Cys 227 of heavy chain.
- An unexpected positional PEG isomer was identified in the CDP870, which contains a PEG at Cys 214 of the light chain.
- Another embodiment of the present invention is a CP870 isomer of having a PEG on Cys 214 of the light chain and a disulfide linkage between the Cys 221 of the heavy chain and Cys 227 of the heavy chain.
- Another embodiment of the present invention is a CP870 isomer of having a PEG on Cys 214 of the light chain and an adduct at Cys 221 of the heavy chain and Cys 227 of the heavy chain.
- the adducts are glutathione(s) or MEA.
- compositions comprises a CDP870 PEG positional isomer, having a PEG attached at Cys 214 of the light chain (CDP870- PEG-1214).
- CDP870-PEG-1214 isomer comprises between about 1% and 20% of the total antibody concentration.
- the CDP870-PEG-1214 isomer comprises between about 1% and 10% of the total antibody concentration.
- the CDP870-PEG-1214 isomer comprises between about 1% and 5% of the total antibody concentration.
- the CDP870- PEG-1214 isomer comprises less than about 5% of the total antibody concentration.
- composition further comprises a CDP870 disulfide isomer, which contains a disulfide linkage between Cys 214 of the light chain and Cys 227 of the heavy chain (1214/h227).
- the CDP870 disulfide isomer (1214/h227) has a PEG attached at Cys 221 of the heavy chain.
- the CDP870-PEG-1214 positional isomer comprises about 1 to 20% of the total antibody concentration and the 1214/h227 disulfide isoform comprises about 20% to 50% of the total CDP870 antibody concentration.
- the CDP870-PEG-1214 positional isomer comprises less than about 5% of the total antibody concentration and the h221/h227 disulfide isoform comprises about 30% to 40% of the total CDP870 antibody concentration.
- the pharmaceutical compositions should preferably comprise a therapeutically effective amount of the antibody of the invention.
- therapeutically effective amount refers to an amount of a therapeutic agent needed to treat, ameliorate or prevent a targeted disease or condition, or to exhibit a detectable therapeutic or preventative effect.
- the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models, usually in rodents, rabbits, dogs, pigs or primates. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
- an effective amount for a human subject will depend upon the severity of the disease state, the general health of the subject, the age, weight and gender of the subject,' diet, time and frequency of administration, drug combination(s), reaction sensitivities and tolerance/response to therapy. This amount can be determined by routine experimentation and is within the judgement of the clinician.
- an effective dose will be from 0.0 1 mg/kg to 50 mg/kg, preferably 0.1 mg/kg to 20 mg/kg, more preferably about 15 mg kg. As shown in the Examples below, doses of 1, 5 and 20 mg/kg have been used to treat patients suffering from rheumatoid arthritis.
- compositions may be administered individually to a patient or may be administered in combination with other agents, drugs or hormones.
- the dose at which the antibody molecule of the present invention is administered depends on the nature of the condition to be treated, the degree to which the level of TNF ⁇ to be neutralised is, or is expected to be, raised above a desirable level, and on whether the antibody molecule is being used prophylactically or to treat an existing condition.
- suitable doses of the antibody molecule of the present invention lie in the range of between 0.5 and 50 mg/kg, more preferably between 1 and 20 mg/kg and most preferably about 15 mg/kg.
- the frequency of dose will depend on the half-life of the antibody molecule and the duration of its effect.
- the antibody molecule has a short half-life (e.g. 2 to 10 hours) it may be necessary to give one or more doses per day.
- the antibody molecule has a long half life (e.g.
- a pharmaceutical composition may also contain a pharmaceutically acceptable carrier for administration of the antibody.
- the carrier should not itself induce the production of antibodies harmful to the individual receiving the composition and should not be toxic.
- Suitable carriers may be large, slowly metabolised macromolecules such as proteins, polypeptides, liposomes, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers and inactive virus particles.
- Pharmaceutically acceptable salts can be used, for example mineral acid salts, such as hydrochlorides, hydrobromides, phosphates and sulphates, or salts of organic acids, such as acetates, propionates, malonates and benzoates.
- Pharmaceutically acceptable carriers in therapeutic compositions may additionally contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents or pH buffering substances, may be present in such compositions. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries and suspensions, for ingestion by the patient.
- Preferred forms for administration include forms suitable for parenteral administration, e.g. by injection or infusion, for example by bolus injection or continuous infusion.
- the product may take the form of a suspension, solution or emulsion in an oily or aqueous vehicle and it may contain formulatory agents, such as suspending, preservative, stabilising and/or dispersing agents.
- the antibody molecule may be in dry form, for reconstitution before use with an appropriate sterile liquid.
- the compositions of the invention can be administered directly to the subject.
- the subjects to be treated can be animals. However, it is preferred that the compositions are adapted for administration to human subjects.
- compositions of this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra- arterial, intramedullary, intrathecal, intraventricular, transdermal, transcutaneous (for example, see W098/20734), subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, intravaginal or rectal routes. Hyposprays may also be used to administer the pharmaceutical compositions of the invention.
- the therapeutic compositions may be prepared as injectables, either as liquid solutions or suspensions. Solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared.
- Direct delivery of the compositions will generally be accomplished by injection, subcutaneously, intraperitoneally, intravenously or intramuscularly, or delivered to the interstitial space of a tissue.
- the compositions can also be administered into a lesion. Dosage treatment may be a single dose schedule or a multiple dose schedule.
- the active ingredient in the composition will be an antibody molecule. As such, it will be susceptible to degradation in the gastrointestinal tract. Thus, if the composition is to be administered by a route using the gastrointestinal tract, the composition will need to contain agents which protect the antibody from degradation but which release the antibody once it has been absorbed from the gastrointestinal tract.
- the present invention also provides the antibody molecule or compositions of the present invention for use in treating a disease mediated by
- the present invention further provides the use of the antibody molecule or composition according to the present invention in the manufacture of a medicament for the treatment of a disease mediated by TNF ⁇ .
- the antibody molecule or composition of the present invention may be utilised in any therapy where it is desired to reduce the level of biologically active TNF ⁇ present in the human or animal body.
- the TNF ⁇ may be circulating in the body or present in an undesirably high level localised at a particular site in the body.
- TNF ⁇ is implicated in acute and chronic immune and immunoregulatory disorders, infections including septic, endotoxic and cardiovascular shock, inflammatory disorders, neurodegenerative diseases, malignant diseases and alcohol induced hepatitis. Details of the numerous disorders associated with elevated levels of TNF ⁇ , are set out in US 5,919,452.
- the antibody molecule or composition of the present invention may be utilised in the therapy of diseases mediated by TNF ⁇ .
- Particularly relevant diseases which may be treated by the antibody molecule of the present invention include sepsis, congestive heart failure, septic or endotoxic shock, cachexia, adult respiratory distress syndrome, AIDS, allergies, psoriasis, TB, inflammatory bone disorders, blood coagulation disorders, bums, rejection episodes following organ or tissue transplant, Crohn's disease and autoimmune diseases, such as thyroiditis and rheumatoid- and osteo-arthritis.
- the antibody molecule or composition may be used: to reduce side effects associated with TNF ⁇ generation during neoplastic therapy; to eliminate or reduce shock-related symptoms associated with the treatment or prevention of graft rejection by use of an anti-lymphocyte antibody; or for treating multi-organ failure.
- the antibody molecule or composition of the present invention is preferably used for treatment of rheumatoid- or osteo-arthritis.
- the present invention also provides a method of treating human or animal subjects suffering from or at risk of a disorder mediated by TNF ⁇ , the method comprising administering to the subject an effective amount of the antibody molecule or composition of the present invention.
- the antibody molecule or composition of the present invention may also be used in diagnosis, for example in the in vivo diagnosis and imaging of disease states involving elevated levels of TNF ⁇ .
- a CDP870 PEG positional isomer is produced in manufacturing where the branched PEG maleimide is conjugated to Cys 214 residue of the light chain, instead of the target Cys227 of the heavy chain.
- This material was identified by analysis of (1) peptide-PEG fragments separated by HPLC and analyzed by N- terminal sequencing and (2) the identification of non-pegylated heavy chain and pegylated light chain in extracts from reducing SDS-PAGE gel electrophoresis. Other techniques such as denaturing size exclusion HPLC have corroborated these findings.
- the reduction of samples to unpegylated heavy chain is evidence that the heavy/light chain association in the PEG positional isomer is due to noncovalent forces other than a disulfide bond.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- AIDS & HIV (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003240790A AU2003240790A1 (en) | 2002-05-28 | 2003-05-28 | Antibody peg positional isomers, compositions comprising same, and use thereof |
AT03731385T ATE518885T1 (en) | 2002-05-28 | 2003-05-28 | PEG POSITION ISOMER OF AN ANTIBODY TO TNFALPHA (CDP870) |
EP03731385A EP1534753B1 (en) | 2002-05-28 | 2003-05-28 | Peg positional isomer of an anti-tnfalpha antibody (cdp870) |
JP2004506753A JP4418745B2 (en) | 2002-05-28 | 2003-05-28 | Antibody PEG regioisomer, composition containing same and use thereof |
US10/515,677 US7601817B2 (en) | 2002-05-28 | 2003-05-28 | Antibody peg positional isomers, compositions comprising same, and use thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38376502P | 2002-05-28 | 2002-05-28 | |
US60/383,765 | 2002-05-28 | ||
PCT/US2003/008608 WO2003080674A1 (en) | 2002-03-20 | 2003-03-20 | Antibody disulfide isomers, use thereof, and methods of analyzing same |
USPCT/US03/08608 | 2003-03-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003099226A2 true WO2003099226A2 (en) | 2003-12-04 |
WO2003099226A3 WO2003099226A3 (en) | 2004-07-15 |
Family
ID=44352443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/016619 WO2003099226A2 (en) | 2002-05-28 | 2003-05-28 | Antibody peg positional isomers, compositions comprising same, and use thereof |
Country Status (7)
Country | Link |
---|---|
US (1) | US7601817B2 (en) |
EP (1) | EP1534753B1 (en) |
JP (1) | JP4418745B2 (en) |
AT (1) | ATE518885T1 (en) |
AU (1) | AU2003240790A1 (en) |
ES (1) | ES2370710T3 (en) |
WO (1) | WO2003099226A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1495056A1 (en) * | 2002-03-20 | 2005-01-12 | Celltech R & D Limited | Antibody disulfide isomers, use thereof, and methods of analyzing same |
EP2046391A2 (en) * | 2006-08-02 | 2009-04-15 | Board Of Regents Of The University Of Nebraska | Drug carriers, their synthesis, and methods of use thereof |
US9101670B2 (en) | 2006-04-07 | 2015-08-11 | Nektar Therapeutics | Conjugates of an anti-TNF-α antibody |
WO2018015428A1 (en) | 2016-07-19 | 2018-01-25 | Richter Gedeon Nyrt. | Novel cell-based tnf-alpha binding assay |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0315457D0 (en) * | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
GB0315450D0 (en) * | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
US5030570A (en) | 1988-06-30 | 1991-07-09 | The Eunice Kennedy Shriver Center For Mental Retardation | DNA encoding and method of expressing human monoamine oxidase type A |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
US5919452A (en) | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
NO309690B1 (en) | 1995-01-23 | 2001-03-12 | Western Atlas Int Inc | Detonator type exploding wire for use with a perforation tool in a well |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
TW428075B (en) | 1999-07-12 | 2001-04-01 | Unit Instr Inc | Pressure insensitive gas control system |
GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
-
2003
- 2003-05-28 WO PCT/US2003/016619 patent/WO2003099226A2/en active Application Filing
- 2003-05-28 EP EP03731385A patent/EP1534753B1/en not_active Expired - Lifetime
- 2003-05-28 US US10/515,677 patent/US7601817B2/en active Active
- 2003-05-28 JP JP2004506753A patent/JP4418745B2/en not_active Expired - Lifetime
- 2003-05-28 AT AT03731385T patent/ATE518885T1/en active
- 2003-05-28 AU AU2003240790A patent/AU2003240790A1/en not_active Abandoned
- 2003-05-28 ES ES03731385T patent/ES2370710T3/en not_active Expired - Lifetime
Non-Patent Citations (2)
Title |
---|
None |
See also references of EP1534753A4 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1495056A1 (en) * | 2002-03-20 | 2005-01-12 | Celltech R & D Limited | Antibody disulfide isomers, use thereof, and methods of analyzing same |
EP1495056A4 (en) * | 2002-03-20 | 2005-09-28 | Celltech R&D Ltd | Antibody disulfide isomers, use thereof, and methods of analyzing same |
US9101670B2 (en) | 2006-04-07 | 2015-08-11 | Nektar Therapeutics | Conjugates of an anti-TNF-α antibody |
US9636412B2 (en) | 2006-04-07 | 2017-05-02 | Nektar Therapeutics | Conjugates of an anti-TNF-alpha antibody |
US10232042B2 (en) | 2006-04-07 | 2019-03-19 | Nektar Therapeutics | Conjugates of an anti-TNF-alpha antibody |
EP2046391A2 (en) * | 2006-08-02 | 2009-04-15 | Board Of Regents Of The University Of Nebraska | Drug carriers, their synthesis, and methods of use thereof |
EP2046391A4 (en) * | 2006-08-02 | 2013-03-20 | Univ Nebraska | Drug carriers, their synthesis, and methods of use thereof |
WO2018015428A1 (en) | 2016-07-19 | 2018-01-25 | Richter Gedeon Nyrt. | Novel cell-based tnf-alpha binding assay |
Also Published As
Publication number | Publication date |
---|---|
JP4418745B2 (en) | 2010-02-24 |
AU2003240790A1 (en) | 2003-12-12 |
AU2003240790A8 (en) | 2003-12-12 |
WO2003099226A3 (en) | 2004-07-15 |
US20060110382A1 (en) | 2006-05-25 |
ATE518885T1 (en) | 2011-08-15 |
EP1534753A4 (en) | 2007-05-09 |
EP1534753B1 (en) | 2011-08-03 |
US7601817B2 (en) | 2009-10-13 |
ES2370710T3 (en) | 2011-12-22 |
JP2005529154A (en) | 2005-09-29 |
EP1534753A2 (en) | 2005-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2707766C (en) | Plasmids ptqomp and ptto-1 which have an ompa signal sequence | |
JP5352761B2 (en) | Antibody disulfide isomers, their use and methods of analysis | |
EP1534753B1 (en) | Peg positional isomer of an anti-tnfalpha antibody (cdp870) | |
JP2005529154A5 (en) | ||
JP2006505497A5 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004506753 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003731385 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003731385 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006110382 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10515677 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10515677 Country of ref document: US |